The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas.
WHO Classification of Tumours Editorial Board. Skin Tumours, 5th ed.; WHO Classification of Tumours Series; Internet, Beta Version Ahead of Print; International Agency for Research on Cancer: Lyon, France, 2023; Volume 12, Available online: https://tumourclassification.iarc.who.int/chapters/64 accessed 20 Jan 2025.
Goodlad JR, Cerroni L, Swerdlow Sh. Recent advances in cutaneous lymphoma-implications for current and future classifications. Virchows Arch. 2022. https://doi.org/10.1007/s00428-022-03421-5.
Article PubMed PubMed Central Google Scholar
Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27–30. https://doi.org/10.1038/NM0195-27.
Article CAS PubMed Google Scholar
Koster A, Raemaekers JMM. Angiogenesis in malignant lymphoma. Curr Opin Oncol. 2005;17:611–6. https://doi.org/10.1097/01.CCO.0000181404.83084.B5.
Angiogenesis in cutaneous T-cell lymphoma - proteomic approaches - PubMed. https://pubmed.ncbi.nlm.nih.gov/30944599/ [Accessed March 27, 2025].
Stolearenco V, Namini MRJ, Hasselager SS, Gluud M, Buus TB, Willerslev-Olsen A, Ødum N, Krejsgaard T. Cellular Interactions and Inflammation in the Pathogenesis of Cutaneous T-Cell Lymphoma. Front Cell Dev Biol. 2020;8: 579897. https://doi.org/10.3389/FCELL.2020.00851/PDF.
Tefferi A, Author MD, Wilcox RA. Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91:151–65. https://doi.org/10.1002/AJH.24233.
Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, Robson A, Calonje E, Stefanato CM, Wain EM, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28:4730–9. https://doi.org/10.1200/JCO.2009.27.7665.
Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973–2002. Arch Dermatol. 2007;143:854–9. https://doi.org/10.1001/ARCHDERM.143.7.854.
Patil K, Kuttikrishnan S, Khan AQ, Ahmad F, Alam M, Buddenkotte J, Ahmad A, Steinhoff M, Uddin S. Molecular pathogenesis of cutaneous T cell lymphoma: role of chemokines, cytokines, and dysregulated signaling pathways. Semin Cancer Biol. 2022;86:382–99. https://doi.org/10.1016/J.SEMCANCER.2021.12.003.
Article CAS PubMed Google Scholar
Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, Ralfkiaer E, Chimenti S, Diaz-Perez JL, Duncan LM, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768–85. https://doi.org/10.1182/BLOOD-2004-09-3502.
Article CAS PubMed Google Scholar
Wen P, Zhuo X, Wang L. Skin barrier dysfunction in cutaneous T-cell lymphoma: from pathogenic mechanism of barrier damage to treatment. Crit Rev Oncol Hematol. 2025;205: 104559. https://doi.org/10.1016/J.CRITREVONC.2024.104559.
Cocks M, Porcu P, Wick MR, Gru AA. Recent advances in cutaneous T-cell lymphoma: diagnostic and prognostic considerations. Surg Pathol Clin. 2019;12:783–803. https://doi.org/10.1016/J.PATH.2019.03.006/ASSET/4895A420-E7AC-4423-9D92-5C59AF16D95A/MAIN.ASSETS/GR18.SML.
Klemke CD, Booken N, Weiss C, Nicolay JP, Goerdt S, Felcht M, Géraud C, Kempf W, Assaf C, Ortonne N, et al. Histopathological and immunophenotypical criteria for the diagnosis of Sézary syndrome in differentiation from other erythrodermic skin diseases: a European Organisation for Research and Treatment of Cancer (EORTC) cutaneous lymphoma task force study of 97 cases. Br J Dermatol. 2015;173:93–105. https://doi.org/10.1111/BJD.13832.
Article CAS PubMed Google Scholar
Horna P, Moscinski LC, Sokol L, Shao H. Naïve/memory T-cell phenotypes in leukemic cutaneous T-cell lymphoma: putative cell of origin overlaps disease classification. Cytometry B Clin Cytom. 2019;96:234–41. https://doi.org/10.1002/CYTO.B.21738.
Article CAS PubMed Google Scholar
Iyer A, Hennessey D, O’Keefe S, Patterson J, Wang W, Wong GKS, Gniadecki R. Skin colonization by circulating neoplastic clones in cutaneous T-cell lymphoma. Blood. 2019;134:1517–27. https://doi.org/10.1182/BLOOD.2019002516.
Gallardo F, Pujol RM. Genetics abnormalities with clinical impact in primary cutaneous lymphomas. Cancers. 2022;14(20):4972. https://doi.org/10.3390/CANCERS14204972.
Article PubMed PubMed Central Google Scholar
Da Silva Almeida AC, Abate F, Khiabanian H, Martinez-Escala E, Guitart J, Tensen CP, Vermeer MH, Rabadan R, Ferrando A, Palomero T. The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome. Nat Genet. 2015;47:1465–70. https://doi.org/10.1038/NG.3442.
Article PubMed PubMed Central Google Scholar
Ungewickell A, Bhaduri A, Rios E, Reuter J, Lee CS, Mah A, Zehnder A, Ohgami R, Kulkarni S, Armstrong R, et al. Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2. Nat Genet. 2015;47(9):1056–60. https://doi.org/10.1038/ng.3370.
Article CAS PubMed PubMed Central Google Scholar
Vaqué JP, Gómez-López G, Monsálvez V, Varela I, Martínez N, Pérez C, Domínguez O, Graña O, Rodríguez-Peralto JL, Rodríguez-Pinilla SM, et al. PLCG1 mutations in cutaneous T-cell lymphomas. Blood. 2014;123:2034–43. https://doi.org/10.1182/BLOOD-2013-05-504308.
Phyo ZH, Shanbhag S, Rozati S. Update on biology of cutaneous T-cell lymphoma. Front Oncol. 2020;10: 507478. https://doi.org/10.3389/FONC.2020.00765.
Yu X, Li H, Zhu M, Hu P, Liu X, Qing Y, Wang X, Wang H, Wang Z, Xu J, et al. Involvement of p53 acetylation in growth suppression of cutaneous T-cell lymphomas induced by HDAC inhibition. J Investig Dermatol. 2020;140:2009-2022.e4. https://doi.org/10.1016/J.JID.2019.12.041/ASSET/9E16E6E5-C609-48C6-BF2B-251C54FD8C0D/MAIN.ASSETS/FX6.JPG.
Article CAS PubMed Google Scholar
Wooler G, Melchior L, Ralfkiaer E, Gjerdrum LMR, Gniadecki R. TP53 gene status affects survival in advanced mycosis fungoides. Front Med (Lausanne). 2016;3: 214352. https://doi.org/10.3389/FMED.2016.00051.
Yanagi T, Nishihara H, Fujii K, Nishimura M, Narahira A, Takahashi K, Iwata H, Hata H, Kitamura S, Imafuku K, et al. Comprehensive cancer-related gene analysis reveals that active KRAS mutation is a prognostic mutation in mycosis fungoides. J Dermatol Sci. 2017;88:367–70. https://doi.org/10.1016/J.JDERMSCI.2017.07.013.
Article CAS PubMed Google Scholar
Sommer VH, Clemmensen OJ, Nielsen O, Wasik M, Lovato P, Brender C, Eriksen KW, Woetmann A, Kaestel CG, Nissen MH, et al. In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia. 2004;18(7):1288–95. https://doi.org/10.1038/sj.leu.2403385.
Article CAS PubMed Google Scholar
Verma NK, Davies AM, Long A, Kelleher D, Volkov Y. STAT3 knockdown by siRNA induces apoptosis in human cutaneous T-cell lymphoma line Hut78 via downregulation of Bcl-xL. Cell Mol Biol Lett. 2010;15:342–55. https://doi.org/10.2478/S11658-010-0008-2.
Article CAS PubMed PubMed Central Google Scholar
Bagherani N, Smoller BR. An overview of cutaneous T cell lymphomas. F1000Res. 2016. https://doi.org/10.12688/F1000RESEARCH.8829.1.
Article PubMed PubMed Central Google Scholar
Kwantwi LB, Rosen ST, Querfeld C. The tumor microenvironment as a therapeutic target in cutaneous T cell lymphoma. Cancers. 2024;16(19):3368. https://doi.org/10.3390/CANCERS16193368.
Article CAS PubMed PubMed Central Google Scholar
Park J, Yang J, Wenzel AT, Ramachandran A, Lee WJ, Daniels JC, Kim J, Martinez-Escala E, Amankulor N, Pro B, et al. Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p. Q575E). Blood. 2017;130:1430–40. https://doi.org/10.1182/BLOOD-2017-02-768234.
Article CAS PubMed PubMed Central Google Scholar
Choi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, Bjornson RD, Maman Y, Wang T, Tordoff J, et al. Genomic landscape of cutaneous T cell lymphoma. Na
Comments (0)